Clinical Trial Update: Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating prophylactic use of Letermovir to prevent CMV infection in kidney transplant recipients at risk for CMV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection in Kidney Transplant Recipients

Drugs mentioned

• Letermovir (letermovir)

Snippet

Sponsor: Hospital do Rim e Hipertensão | Conditions: CMV Infection | Phase 3 | Status: UNKNOWN